Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
PolyPeptide Group AG's operating assets for the quarter that ended in Dec. 2025 was CHF701.1 Mil. PolyPeptide Group AG's operating liabilities for the quarter that ended in Dec. 2025 was CHF331.1 Mil. PolyPeptide Group AG's Total Assets for the quarter that ended in Jun. 2025 was CHF725.1 Mil. Therefore, PolyPeptide Group AG's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.51.
PolyPeptide Group AG Scaled Net Operating Assets Related Terms
PolyPeptide Group AG Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG Scaled Net Operating Assets Chart
XSWX:PPGN vs ZTS, UTHR, VTRS: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.51 mean?
PolyPeptide Group AG (XSWX:PPGN) has a Scaled Net Operating Assets of 0.51 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Scaled Net Operating Assets too high?
PolyPeptide Group AG's current Scaled Net Operating Assets is 0.51. Overall, PolyPeptide Group AG has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Scaled Net Operating Assets compare to ZTS and UTHR?
PolyPeptide Group AG's Scaled Net Operating Assets of 0.51 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Scaled Net Operating Assets is 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF30.80, compared to a current price of CHF49.40 — trading 60.4% above its estimated fair value. The current Scaled Net Operating Assets is 0.51. PolyPeptide Group AG's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Scaled Net Operating Assets is 0.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of CHF49.40 is trading 60.4% above its estimated GF Value™ of CHF30.80.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for XSWX:PPGN:
Scaled Net Operating Assets: 0.51
GF Value™: CHF30.80 vs. price of CHF49.40 (60.4% above fair value)
No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
73GF Score
Get the complete analysis for XSWX:PPGN
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:PPGN has been successfully added to your 
